{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:25:46Z","timestamp":1791318346450,"version":"4.3.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002456","name":"Chonnam National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002456","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2023-00245453"],"award-info":[{"award-number":["RS-2023-00245453"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13318-025-00938-3","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T10:29:21Z","timestamp":1742034561000},"page":"187-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a Physiologically-Based Pharmacokinetic Model for Quantitative Interpretation of Transdermal Drug Delivery of Rotigotine, a Dopamine Agonist for Treating Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"50","author":[{"given":"Ji-Hun","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-0631","authenticated-orcid":false,"given":"Seung-Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","volume":"75","author":"J-P Elshoff","year":"2015","unstructured":"Elshoff J-P, Cawello W, Andreas J-O, Mathy F-X, Braun M. An update on pharmacological, pharmacokinetic properties and drug\u2013drug interactions of rotigotine transdermal system in Parkinson\u2019s disease and restless legs syndrome. Drugs. 2015;75:487\u2013501.","journal-title":"Drugs"},{"issue":"4","key":"938_CR2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/bph.12988","volume":"172","author":"M Wood","year":"2015","unstructured":"Wood M, Dubois V, Scheller D, Gillard M. Rotigotine is a potent agonist at dopamine D 1 receptors as well as at dopamine D 2 and D 3 receptors. Br J Pharmacol. 2015;172(4):1124\u201335.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"938_CR3","volume":"2015","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Restless legs syndrome and leg motor restlessness in Parkinson\u2019s disease. Parkinson\u2019s Disease. 2015;2015(1): 490938.","journal-title":"Parkinson\u2019s Disease."},{"issue":"19","key":"938_CR4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.2174\/1381612826666200316154300","volume":"26","author":"S Md","year":"2020","unstructured":"Md S, Karim S, Saker SR, Gie OA, Hooi LC, Yee PH, et al. Current status and challenges in rotigotine delivery. Curr Pharm Des. 2020;26(19):2222\u201332.","journal-title":"Curr Pharm Des"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2165\/11206750-000000000-00000","volume":"25","author":"M Sanford","year":"2011","unstructured":"Sanford M, Scott LJ. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson\u2019s disease. CNS Drugs. 2011;25:699\u2013719.","journal-title":"CNS Drugs"},{"issue":"11","key":"938_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261\u20138.","journal-title":"Nat Biotechnol"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-016-0610-7","volume":"16","author":"RA Hauser","year":"2016","unstructured":"Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson\u2019s disease. BMC Neurol. 2016;16:1\u201312.","journal-title":"BMC Neurol"},{"issue":"11","key":"938_CR8","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/mds.23157","volume":"25","author":"WA Hening","year":"2010","unstructured":"Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675\u201383.","journal-title":"Mov Disord"},{"issue":"11","key":"938_CR9","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1016\/j.xphs.2022.08.035","volume":"111","author":"S-H Jeong","year":"2022","unstructured":"Jeong S-H, Jang J-H, Lee Y-B. Physiologically Based Pharmacokinetic (PBPK) modeling of lornoxicam: exploration of doses for CYP2C9 genotypes and patients with cirrhosis. J Pharm Sci. 2022;111(11):3174\u201384.","journal-title":"J Pharm Sci"},{"issue":"12","key":"938_CR10","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/pharmaceutics14122720","volume":"14","author":"S-H Jeong","year":"2022","unstructured":"Jeong S-H, Jang J-H, Lee Y-B. Torsemide pharmacometrics in healthy adult populations including CYP2C9 genetic polymorphisms and various patient groups through physiologically based pharmacokinetic-pharmacodynamic modeling. Pharmaceutics. 2022;14(12):2720.","journal-title":"Pharmaceutics"},{"issue":"7","key":"938_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.clinthera.2018.05.009","volume":"40","author":"Y Liu","year":"2018","unstructured":"Liu Y, Tomlinson B, Guo J, Asgharnejad M, Bauer L, Surmann E, et al. Pharmacokinetics, tolerability, and bioequivalence of two formulations of rotigotine in healthy Chinese subjects. Clin Ther. 2018;40(7):1108-21.e8.","journal-title":"Clin Ther"},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13318-018-0460-3","volume":"43","author":"W Cawello","year":"2018","unstructured":"Cawello W, Braun M, Andreas J-O. Drug delivery and transport into the central circulation: an example of zero-order in vivo absorption of rotigotine from a transdermal patch formulation. Eur J Drug Metab Pharmacokinet. 2018;43:475\u201381.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sleep.2016.04.012","volume":"32","author":"J-P Elshoff","year":"2017","unstructured":"Elshoff J-P, Hudson J, Picchietti DL, Ridel K, Walters AS, Doggett K, et al. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis\u2013Ekbom disease). Sleep Med. 2017;32:48\u201355.","journal-title":"Sleep Med"},{"key":"938_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13318-015-0273-6","volume":"41","author":"W Cawello","year":"2016","unstructured":"Cawello W, Kim SR, Braun M, Elshoff J-P, Masahiro T, Ikeda J, et al. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration. Eur J Drug Metab Pharmacokinet. 2016;41:353\u201362.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"938_CR15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.clinthera.2015.01.013","volume":"37","author":"B-H Kim","year":"2015","unstructured":"Kim B-H, Yu K-S, Jang I-J, Lim KS, Kim J-R, Elshoff J-P, et al. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy Korean volunteers. Clin Ther. 2015;37(4):902\u201312.","journal-title":"Clin Ther"},{"issue":"3","key":"938_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/cpdd.78","volume":"3","author":"JP Elshoff","year":"2014","unstructured":"Elshoff JP, Cawello W, Andreas JO, Braun M. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine. Clin Pharmacol Drug Dev. 2014;3(3):187\u201393.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40261-013-0150-5","volume":"34","author":"W Cawello","year":"2014","unstructured":"Cawello W, Kim SR, Braun M, Elshoff J-P, Ikeda J, Funaki T. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clin Drug Investig. 2014;34:95\u2013105.","journal-title":"Clin Drug Investig"},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13318-013-0153-x","volume":"39","author":"W Cawello","year":"2014","unstructured":"Cawello W, Fichtner A, Boekens H, Braun M. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet. 2014;39:155\u201363.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"938_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1185\/03007995.2013.841666","volume":"29","author":"J-P Elshoff","year":"2013","unstructured":"Elshoff J-P, Timmermann L, Schmid M, Arth C, Komenda M, Brunnert M, et al. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. Curr Med Res Opin. 2013;29(12):1657\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"938_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.clinthera.2012.02.008","volume":"34","author":"J-P Elshoff","year":"2012","unstructured":"Elshoff J-P, Braun M, Andreas J-O, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34(4):966\u201378.","journal-title":"Clin Ther"},{"issue":"1","key":"938_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2125.2011.04053.x","volume":"73","author":"W Cawello","year":"2012","unstructured":"Cawello W, Ahrweiler S, Sulowicz W, Szymczakiewicz-Multanowska A, Braun M. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol. 2012;73(1):46\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"938_CR22","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1124\/dmd.109.027383","volume":"37","author":"W Cawello","year":"2009","unstructured":"Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009;37(10):2055\u201360.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"938_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2125.2008.03334.x","volume":"67","author":"M Braun","year":"2009","unstructured":"Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol. 2009;67(2):209\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"938_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1177\/0091270009338481","volume":"49","author":"M Braun","year":"2009","unstructured":"Braun M, Cawello W, Andreas JO, Math D, Boekens H, Horstmann R. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa\/carbidopa. J Clin Pharmacol. 2009;49(9):1047\u201355.","journal-title":"J Clin Pharmacol"},{"key":"938_CR25","unstructured":"DrugBank. Rotigotine. https:\/\/go.drugbank.com\/drugs\/DB05271. Accessed 20 Nov 2024."},{"issue":"11","key":"938_CR26","first-page":"12","volume":"5","author":"P Ravisankar","year":"2015","unstructured":"Ravisankar P, Reddy AA, Nagalakshmi B, Koushik OS, Kumar BV, Anvith PS. The comprehensive review on fat soluble vitamins. IOSR J Pharm. 2015;5(11):12\u201328.","journal-title":"IOSR J Pharm."},{"key":"938_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109319","volume":"183","author":"J-H Jang","year":"2024","unstructured":"Jang J-H, Jeong S-H. Population pharmacokinetic modeling study and discovery of covariates for the antidepressant sertraline, a serotonin selective reuptake inhibitor. Comput Biol Med. 2024;183: 109319.","journal-title":"Comput Biol Med"},{"issue":"4","key":"938_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bcp.15991","volume":"90","author":"H Sun","year":"2024","unstructured":"Sun H, Dong C, Wu M, Li X, Song H, Zhang Y, et al. Population pharmacokinetics of rotigotine extended-release microspheres for intramuscular injection in patients with early-stage Parkinson\u2019s disease. Br J Clin Pharmacol. 2024;90(4):1094\u2013102.","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00938-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00938-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00938-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T14:09:42Z","timestamp":1747318182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00938-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00938-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"25 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ji-Hun Jang: Conceptualization, Investigation, Methodology, Formal analysis, Data curation, Software, Writing - Original draft preparation, Reviewing and Editing; Seung-Hyun Jeong: Conceptualization, Investigation, Methodology, Project administration, Funding acquisition, Formal analysis, Supervision, Data curation, Software, Writing - Original draft preparation, Reviewing and Editing","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This study was financially supported by Chonnam National University (Grant number: 2024-1949).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All data and related materials are accessible in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors have no conflicts of interest relevant to this study to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}